Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfurous Acid SCHEMBL7770697 | 0.96 | CA1 (0.43) | CA1CA2HIF1AALDH1A1TSHR | |
| Sulfurous Acid SCHEMBL10414559 | 0.96 | CA1 (0.43) | CA1CA2HIF1AALDH1A1TSHR | |
| Glutaral SCHEMBL8620854 | 0.86 | HIF1A (0.67) | CA1CA2HIF1AALDH1A1TSHR | |
| Glutaral SCHEMBL3241155 | 0.86 | HIF1A (0.67) | CA1CA2HIF1AALDH1A1TSHR | |
| Sulfurous Acid SCHEMBL8002563 | 0.83 | HIF1A (0.37) | HIF1AALDH1A1TSHR | |
| Glutaral SCHEMBL6775101 | 0.83 | HIF1A (0.62) | CA1CA2HIF1AALDH1A1TSHR | |
| Sulfurous Acid SCHEMBL7770699 | 0.83 | HIF1A (0.37) | HIF1AALDH1A1TSHR | |
| Glutaral SCHEMBL8434890 | 0.83 | HIF1A (0.62) | CA1CA2HIF1AALDH1A1TSHR | |
| Glutaral SCHEMBL9440845 | 0.83 | HIF1A (0.62) | CA1CA2HIF1AALDH1A1TSHR | |
| Butanal SCHEMBL7550402 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158941-A1 | Gold Plating Bath and Gold Plated Final Finish | MACDERMID ENTHONE INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4158079-A1 | GOLD PLATING BATH AND GOLD PLATED FINAL FINISH | MacDermid Enthone Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| US-7229987-B2 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | ELI LILLY AND COMPANY (US) | 2007-06-12 | — | — | US | disclosed |
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | AMMENN ET AL, JOCHEN | 2005-12-08 | — | — | US | disclosed |
| EP-1505968-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003097047-A1 | MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES | ELI LILLY AND COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272718-A1 | Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes | MC1R, MC4R, MC5R | CA1 4138/4885CA2 1419/4885HIF1A 1918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.